# Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

> **NCT07414212** · PHASE1,PHASE2 · RECRUITING · sponsor: **Biogipuzkoa Health Research Institute** · enrollment: 90 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Acetylcysteine
- **DIETARY_SUPPLEMENT:** EH301
- **DRUG:** Riluzole

## Key facts

- **NCT ID:** NCT07414212
- **Lead sponsor:** Biogipuzkoa Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2026-11-25
- **Final completion:** 2027-11-25
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07414212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07414212, "Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07414212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*